Five-Year Data Shows Moderna-Merck Cancer Vaccine Holds Its Power Against Melanoma

A personalized cancer vaccine developed by Moderna and Merck continues to show strong results years after treatment, offering new evidence for a promising approach to stopping melanoma's return. Updated findings released in early 2026 reveal that, five years after starting therapy, the mRNA-based vaccine given with Merck's immunotherapy Keytruda reduced the risk of cancer recurrence or death by 49% compared to Keytruda alone.

The data, from a mid-stage study of 157 patients with high-risk melanoma, indicates the treatment's effect is not only substantial but durable. The benefit appears even greater in preventing the cancer from spreading to distant parts of the body, with a 62% reduction in risk. For patients who received the combination, 75.3% were alive without their cancer returning after five years, versus 55.6% for those on the standard treatment.

This vaccine, known as mRNA-4157, is custom-made for each patient. Scientists analyze a patient's surgically removed tumor, identify its unique genetic signatures, and create a vaccine designed to train the immune system to hunt for any remaining cancer cells bearing those markers. It represents a shift from one-size-fits-all treatments to highly tailored medicine.

The partnership is now testing this strategy in larger, final-stage trials for melanoma and has expanded research into other cancers, including lung and kidney cancers. While questions about manufacturing complexity and cost remain, the sustained five-year results provide a solid foundation for what could become a new standard of care, turning a page in the long effort to use the body's own defenses against cancer.

Source: Webpronews